Advertisement

Fall 66: Therapie – 57 Jahre, ♂, DM Typ 2, koronare Herzerkrankung

  • Alba Sulaj
Chapter

Zusammenfassung

Ein 57-jähriger Patient mit koronarer Herzerkrankung und einem Diabetes Typ 2 seit 8 Jahren ist mit Glibenclamid und Metformin auf einem HbA1c von 6,8 eingestellt. Soll die Medikation so belassen werden?

Literatur

  1. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, HGG (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53(12):2546–2553CrossRefGoogle Scholar
  2. Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2014) Therapie des Typ-2-Diabetes – Leitlinien-Report. Nationale VersorgungsLeitlinie 1. Auflage (Version 3. 2014, zuletzt verändert: Februar 2015).  https://doi.org/10.6101/azq/000226
  3. Evans JM, Ogston SA, Emslie-Smith A, DMA (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49(5):930–936Google Scholar
  4. Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, AH (2013) Association of sulfonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 10(4):302–314CrossRefGoogle Scholar
  5. Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrom SZ, Torp-Pedersen C, RHP (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study. Cardiovasc Diabetol 9(54)Google Scholar
  6. Lamanna C, Monami M, Marchionni N, EM (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13(3):221–228CrossRefGoogle Scholar
  7. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, SZR (2010) The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 33(6):1224–1229CrossRefGoogle Scholar
  8. Rao AD, Kuhadiya N, Reynolds K, AFV (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31(8):1672–1678CrossRefGoogle Scholar
  9. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, CT-P (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32(15):1900–1908Google Scholar
  10. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, PE (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339(-):b4731Google Scholar
  11. UK Prospective Diabetes Study (UKPDS) Group (1998a) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865CrossRefGoogle Scholar
  12. UK Prospective Diabetes Study (UKPDS) Group (1998b) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853CrossRefGoogle Scholar
  13. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, TS (2010) Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 95(11):4993–5002Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations